Form 4: FibroGen CEO Wettig Reports Stock Transactions

FibroGen CEO Thane Wettig reports the acquisition and disposal of company stock related to vesting of restricted stock units and PSU milestone grants.

Summary

• On March 6, 2025, FibroGen CEO Thane Wettig reported transactions involving FibroGen common stock.
• 22,038 shares were disposed of at $0.39 per share to cover tax obligations related to vesting restricted stock units.
• 781 shares were acquired at $0 related to a PSU Milestone Grant vesting.
• 367 shares were disposed of at $0.39 per share to cover tax obligations related to the vesting of the PSU Milestone Grant.
• Following these transactions, Wettig directly owns 398,329 shares of common stock and indirectly owns 1,000 shares through a spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports routine stock transactions related to executive compensation. There is no indication of unusual or concerning activity.

Positives

• The vesting of PSU Milestone Grants suggests the achievement of certain performance targets within FibroGen.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.

Key Dates